UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2012
| Apricus Biosciences, Inc. |
| (Exact name of registrant as specified in its charter) |
| Nevada | 0-22245 | 87-0449967 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| 11975 El Camino Real, Suite 300, San Diego, CA | 92130 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (858) 222-8041
(Former name or former address, if changed, since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
| Item 8.01 | Other Events. |
On October 4, 2012, NexMed (U.S.A.), Inc., a wholly-owned subsidiary of Apricus Biosciences, Inc. (the “Company”), entered into an additional new work order (the “Work Order”) pursuant to its Vitaros® Cream Clinical Supply Agreement, effective as of January 30, 2012 (the “Supply Agreement”) with Warner Chilcott UK Limited (together with its affiliates “WC”).
Under the Work Order, the Company will receive approximately $682,000 payment for stability testing of its Vitaros® product, in addition to the approximately $450,000 amount to be received by the Company under the Supply Agreement and a prior work order.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Apricus Biosciences, Inc. | |||
| By: | /s/ Randy Berholtz | ||
| Name: Randy Berholtz | |||
| Title: Executive Vice President, General Counsel and Secretary | |||
| Date: October 9, 2012 | |||